RELIEF THERAPEUTICS : announces today its financial results for the year ended 2017

Geneva, Switzerland, 1 May2018

RELIEF THERAPEUTICS Holding SA ('Relief', the 'Company') published its financial results for the year 2017 on 30 April 2018.

The Company generated consolidated revenues of CHF zero and a net result of minus CHF 2.887 million for the year ended 31 December 2017, compared to revenues of CHF 15'000 and a net result of minus CHF 16.8 million for the same period in 2016. This difference mainly arises out of a recognized impairment of goodwill that has been applied in 2016 and not in 2017.

As previously disclosed in July 2016, the Company (formerly THERAMetrics holding AG) acquired 100% of Relief Therapeutics SA ('Relief SA') of Geneva. Due to the fact that the former owners of Relief SA are now the majority shareholders of Relief Therapeutics Holding, the transaction has been treated as reverse acquisition in accordance with the IFRS accounting principles. Accordingly, the consolidated financial statements are shown as a continuation of the financial statements of Relief SA and not THERAMetrics holding AG.

Raghuram Selvaraju, Chairman of the Board of Directors, comments: 'The 2017 financial statements published today reflect the results of the first full year of transition of the Company following its merger with THERAMetrics in 2016. Consolidation of the Company has been pursued this year by the new Executive Committee who made constructive efforts to assure that the Company remains fully operational. In addition, Relief has recently established a number of collaborations and licensing deals that we hope will set the stage for a new drive for Relief to demonstrate the innovative and therapeutic potential of its Medicinal Products Candidates for the benefit of patients and shareholders.'

The 2017 annual report is available here.

About Relief Therapeutics Holding AG

RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are Aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (Atexakin Alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin Alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, and has been the subject of multiple clinical trials. Based on its unique mechanism of action, Atexakin Alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Geneva, Switzerland.

For further information, please visit the Relief website at www.relieftherapeutics.com or contact investor relations at:

RELIEF THERAPEUTICS Holding SA

Investor Relations

[e-mail]

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.